Clinical Trial Search

Primary: Patient Survival at Day-30 Post Transplant and Absence of Severe Primary Heart Graft Dysfunction in the First 24 Hours Post-transplantation — 66 Participants — p=<0.0001

Primary: To Evaluate the Efficacy of Intramuscular Administration of Engensis on Reducing Pain in Participants With Painful Diabetic Peripheral Neuropathy in the Feet and Lower…

Primary: Cluster Size — 1.81; 1.41 outbreak cases after first signal

Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 6; 4; 1 Participants

Primary: Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score — 1; 7; 6; 6 Participants — p=0.0324

Primary: Acute and Late Genitourinary and Lower Gastrointestinal Toxicity Using the Radiation Therapy Oncology Group Acute and Late Morbidity Scales. — 11; 0; 0; 0 participants

Primary: Survival Rate at End of 1 Year — 79.3 percentage of participants

Primary: The Percentage of Responders on the 5-point Mid-Face Volume Deficit Severity Scale (MVDSS) at Week 24 - Per Protocol Dataset — 268; 124 Participants — p=<0.0001

Primary: Corneal Thickness — 542.23; 546.16; 544.32 microns

Primary: Number of Adverse Events From Baseline Through the Last Treatment Visit (up to Week 268) — 8119 events

Primary: Least Square Mean Change in Baseline to Week 8 on Z-score in Combined Digit Symbol Substitution Test (DSST) — 0.332; 0.184 score on a scale

Primary: Percentage of Patients That Respond to Treatment — 18 Participants

Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) — 66.7; 41.7; 16.7; 0 Percentage of participants

Primary: Number of Participants With Subjectively Bothersome Stress Incontinence — 129; 126 Participants

Primary: Number of Participants With Electronic Health Record-verified Completion of a Chest CT Scan — 164; 113 Participants